Company / R&D Expense
Revolution Medicines, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$987.3M
FY2025
5-year range
$91.8M / $987.3M
FY2021-FY2025
Trend
+66.7%
vs FY2024
Sector context
#18 of 210
Health Care
What the data says
Among 210 Health Care companies, Revolution Medicines, Inc. is in the top 9% for r&d expense. R&D Expense has increased for 5 consecutive years, from $51M in FY2020 to $987M in FY2025.
Based on SEC 10-K filings.
$987M in FY2025 with a 5-year CAGR of +80.8%. Top quartile in the Health Care sector.
Improved from $423M to $987M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +95.4%
- 5-Year CAGR
- +80.8%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 210This company $987.3M Sector average $644.0M
▼
+53.3% above sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +80.8%, indicating consistent growth.
- In FY2025, r&d expense increased 66.7% year-over-year.
- Ranks #18 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $987.3M | +66.7% |
| FY2024 | $592.2M | +40.0% |
| FY2023 | $423.1M | +220.0% |
| FY2022 | $132.3M | +44.1% |
| FY2021 | $91.8M | +79.6% |
| FY2020 | $51.1M | -44.3% |
| FY2019 | $91.8M | +79.6% |
| FY2018 | $51.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026